Summary.-The procoagulant activity of cells from some experimental tumours isolated in culture or in single-cell suspensions from ascitic fluid was investigated. Cells from Lewis lung carcinoma (primary and metastasis), Ehrlich carcinoma ascites and JW sarcoma ascites were able to shorten markedly the recalcification time of normal, Factor VIII-and Factor VII-deficient but not of Factor X-deficient human plasma. The same cells generated thrombin when mixed with a source of prothrombin and Factor X, absorbed bovine serum (as a source of Factor V), phospholipid and calcium chloride. Thrombin formation was not influenced by the presence of Factor VII. Cells from Sarcoma 180 ascites were completely inactive in both test systems. It is concluded that cells from some experimental tumours have the capacity to activate Coagulation Factor X directly. These findings suggest the existence of an alternative "cellular" pathway in the initiation of blood clotting distinct from both the intrinsic and extrinsic mechanisms.
DEPOSITION of fibrin within and around tumours has been observed by several authors, although its precise role in tumour growth and metastasis formation has not yet been completely clarified (Hiramoto et al., 1960; Ogura et al., 1970; Peterson, 1977) . On the other hand, it has been known for several years that malignant disease is associated with a high incidence of vascular thrombosis or disseminated intravascular coagulation (Slichter & Harker, 1974; Pineo et al., 1974; Goodnight, 1974) .
The mechanism of activation of coagulation by cancer cells still remains uncertain. This has led several investigators to look for procoagulant activities in malignant tissues. Procoagulant activity with characteristics of tissue thromboplastin has been found in human benign and malignant tumours (O'Meara, 1958; Boggust et al., 1968; Svanberg, 1975; Sakuragawa et al., 1977) and in some experimental tumours (Frank & Hlolvoke, 1968; Holyoke et al., 1972) . Pineo et al. (1973 Pineo et al. ( , 1974 reported that partially purified mucin from secretions of non-purulent chronic bronchitis, ovarian cyst fluid and saliva, as well as extracts of mucinproducing adenocarcinomas directly activated Coagulation Factor X, and suggested that this procoagulant might play a role in the coagulation disorders of patients with mucus-secreting adenocarcinomas. A similar activity was subsequently described by Gordon et al. (1975) in extracts from human malignant tissues and from an experimental tumour (rabbit Xr2 carcinoma) but not in extracts from normal tissues. This activity appeared to be related to the presence in the extracts of a serum protease called Cancer Procoagulant A (CPA; Gordon et al., 1975 al., 1965 al., : Frindel et al., 1967 Simpson-Herren et al.. 1974 : Poggi et al., 1977 .
As the tumour has very poor cohesion, it can normally be disaggregated mechanically. (Janik, 1976 Clotting time was determined wsith a mixture of 0-1 ml plasma, 0-1 ml cell suspension or PBS and 041 ml 0-02M CaC12-2. Assay for Factor-X-activating activity.
This was also a one-stage coagulation time imeasured on the following mixture: 0-1 ml cell suspension or PBS, 0-05 ml phospholipid, 0-05 ml absorbed bovine serum (as a source of Factor V). 0-05 ml partial prothrombincomplex concentrate (PCC), 0-1 inl purified human fibrinogen (2 mg/ml) and 041 ml 0-05M CaC12. This test system, adapted from the one described for platelet coagulant activity by Semeraro & Vermylen (1977) selectively measures direct activation of Factor X (Fig. 1) Table I shows the effect of cells on plasma recalcification time. Here the results of experiments with 2 or more preparations of the same cell type are reported.
Cells from 3LL (primary and metastasis) and Eh.ca markedly shortened the recalcification time of normal plasma and Thrombofax-Ortho, used as phospholipid, was obtained from Cilag-Chemie, Milan, Italy, and purified human fibrinogen from Kabi AB, Stockholm, Sweden. Bovine serum, used as a source of Factor V, was absorbed by 150 mg/ml barium sulphate (Merck, Darmstadt, Germany); after absorption this serum had about 1 u/ml Factor V activity. Partial prothrombin-complex concentrate (Prothromplex, kindly supplied by Immuno AG, Vienna, Austria) was dissolved in isotonic saline and diluted immediately before use to obtain a solution containing 1 u/ml of prothrombin and Factor X. This preparation contained about 0.1 u/ml of Factor VII and had no thrombin and Factor Xa activity according to previously defined criteria (Semeraro & Vermylen, 1977 fluenced the recalcification time of Factor X-deficient plasma. The effects observed were dependent upon cell numbers; a typical experiment is reported in Fig. 2 for 3LL cells. Disruption of all the cell types studied by freezing and thawing (vX 3) or by sonication did not, modify their coagulant activities. double-logarithmic paper against the corresponding dilutions, a straight line resulted which was parallel to the one relating different Eh.ca cell numbers and the corresponding clotting times (Fig. 3) .
DISCIJSSION
Cell suspensions from some experimental tumours have procoagulant activity, as demonstrated by the marked shortening of the clotting time of normal plasma after recalcification. Experiments were therefore made to elucidate the mechanism by which cancer cells accelerated blood clotting in our experimental conditions. Except S180, all the cancer cells studied shortened the one-stage recalcification time of Factor V1III-and of Factor VIIdeficient, plasmas to a similar extent. The possibility that coagulation factors adsorbed to cells might be responsible for these effects is unlikely. Cell activity was clearly seen in normal plasma, i.e. in the presence of large amounts of all the clotting factors. In addition, it, remained with the cells after multiple washings. Since cancer cells did not require either Factor V'III or VII, which are key proteins in intrinsic and extrinsic clotting respectively, most probably they did not act by either of these pathways. Factor Xa may have been formed in vivo in the case of Eh.ca and JWS ascites and then adsorbed on to the cells; alternatively, the foetal calf serum added to the culture medium might contain trace amounts of Factor Xa, possibly adsorbed on 3LL cells. If this were the case, using Factor-X-deficient plasma instead of normal, Factor VIII-or VII-deficient plasma, would make no difference in the recalcification time.
In fact the cancer cells failed to shorten markedly the clotting time of Factor-Xdeficient plasma. This observation also ruled out the possibility that cells were acting on prothrombin or fibrinogen. The most likely explanation for our results is that cancer cells themselves possess Factor-X-activating activity. The slight shortening in Factor-X-deficient plasma substrate may be due, at least in part, to the presence of small amounts of Factor X in the substrate. Our contention that the cancer cells studied have this peculiar procoagulant activity (Factor X activation) was supported by the results with a relatively purified, sensitive and specific test system (see Materials and Methods and Results sections).
In this assay, only the cells which shortened plasma clotting time were able to generate thrombin; S1 80 and the control cell line L929 were completely ineffective. Using control cells with thromboplastin-like activity (FET) it was clearly shown that our assay readily discriminates between direct and Factor ViI1-mediated activation of Factor X. Taken altogether our findings suggest the existence of an alternative "cellular" pathway in bloodclotting initiation distinct from both intrinsic and extrinsic mechanisms. A coagulant activity directly activating Factor X has recently been described in human and animal (rabbit, rat, guineapig) platelets (Semeraro & Vermylen, 1977; Semeraro et al., 1979; Tremoli et al., 1977) .
This study confirms and extends the results obtained by Gordon et al. (1975) 
